Literature DB >> 6307225

Infection of laboratory rats with a new cytomegalo-like virus.

C A Bruggeman, W M Debie, G Grauls, G Majoor, C P van Boven.   

Abstract

This report described the infection of two strains of laboratory rats with a ratvirus (RA-1) with cytomegalovirus-like characteristics. The virus was detected in the spleens and kidneys during the first week post infection. In the salivary glands maximal virus titer was reached at one month post infection; thereafter the titer declined. In Lewis rats virus could be detected in the salivary homogenate of most animals at more than 12 months post infection. In BN rats, in contrast, virus became undetectable in the salivary glands of most animals 5 months after inoculation. However, administration of cyclophosphamide or X-irradiation resulted in reactivation of the virus in virtually all animals. Co-cultivation of spleen cells from either latently or chronically infected animals resulted in recovery of virus. The animals developed antibodies and a T-cell mediated virus specific cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6307225     DOI: 10.1007/bf01311103

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  14 in total

1.  Activation of latent murine cytomegalovirus infection: cocultivation, cell transfer, and the effect of immunosuppression.

Authors:  D Mayo; J A Armstrong; M Ho
Journal:  J Infect Dis       Date:  1978-12       Impact factor: 5.226

2.  A rapid method for the separation of functional lymphoid cell populations of human and animal origin on PVP-silica (Percoll) density gradients.

Authors:  J T Kurnick; L Ostberg; M Stegagno; A K Kimura; A Orn; O Sjöberg
Journal:  Scand J Immunol       Date:  1979       Impact factor: 3.487

Review 3.  The murine cytomegalovirus as a model for the study of viral pathogenesis and persistent infections.

Authors:  J B Hudson
Journal:  Arch Virol       Date:  1979       Impact factor: 2.574

4.  Cytotoxic T lymphocyte response to murine cytomegalovirus infection.

Authors:  G V Quinnan; J E Manischewitz; F A Ennis
Journal:  Nature       Date:  1978-06-15       Impact factor: 49.962

5.  Plaque assay of cytomegalovirus strains of human origin.

Authors:  B B Wentworth; L French
Journal:  Proc Soc Exp Biol Med       Date:  1970-11

6.  Murine cytomegalovirus infection in the spleen and its relationship to immunosuppression.

Authors:  L Loh; J B Hudson
Journal:  Infect Immun       Date:  1981-06       Impact factor: 3.441

7.  Latent cytomegalovirus infection of BALB/c mouse spleens detected by an explant culture technique.

Authors:  T G Wise; J E Manischewitz; G V Quinnan; G S Aulakh; F A Ennis
Journal:  J Gen Virol       Date:  1979-08       Impact factor: 3.891

8.  Comparison of guinea pig cytomegalovirus and guinea pig herpes-like virus: pathogenesis and persistence in experimentally infected animals.

Authors:  R B Tenser; G D Hsiung
Journal:  Infect Immun       Date:  1976-03       Impact factor: 3.441

9.  Isolation of a cytomegalovirus-like agent from wild rats.

Authors:  C A Bruggeman; H Meijer; P H Dormans; W M Debie; G E Grauls; C P van Boven
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

10.  Cytomegalovirus infection in weanling guinea pigs.

Authors:  W S Connor; K P Johnson
Journal:  J Infect Dis       Date:  1976-11       Impact factor: 5.226

View more
  17 in total

1.  Treatment of experimental cytomegalovirus infections with acyclovir.

Authors:  C A Bruggeman; W Engels; J Endert
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

2.  Rat cytomegalovirus gene expression in cardiac allograft recipients is tissue specific and does not parallel the profiles detected in vitro.

Authors:  Daniel N Streblow; Koen W R van Cleef; Craig N Kreklywich; Christine Meyer; Patricia Smith; Victor Defilippis; Finn Grey; Klaus Früh; Robert Searles; Cathrien Bruggeman; Cornelis Vink; Jay A Nelson; Susan L Orloff
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

3.  The development and characterization of monoclonal antibodies against rat cytomegalovirus induced antigens.

Authors:  J H Bruning; W H Debie; P H Dormans; H Meijer; C A Bruggeman
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

Review 4.  Animal cytomegaloviruses.

Authors:  J Staczek
Journal:  Microbiol Rev       Date:  1990-09

5.  Structure of the rat cytomegalovirus genome termini.

Authors:  C Vink; E Beuken; C A Bruggeman
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

6.  Rat cytomegalovirus induces cellular purine and pyrimidine nucleoside kinases in rat embryo fibroblasts and TK- rat-2 cells. Correlations with the antiviral activity of Acyclovir.

Authors:  H Meijer; C A Bruggeman; P H Dormans; C P van Boven
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

7.  Dissemination of rat cytomegalovirus through infected granulocytes and monocytes in vitro and in vivo.

Authors:  B W A van der Strate; J L Hillebrands; S S Lycklama à Nijeholt; L Beljaars; C A Bruggeman; M J A Van Luyn; J Rozing; T H The; D K F Meijer; G Molema; M C Harmsen
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?

Authors:  Mark R Schleiss
Journal:  Future Virol       Date:  2013-12       Impact factor: 1.831

9.  Triple drug immunosuppression significantly reduces immune activation and allograft arteriosclerosis in cytomegalovirus-infected rat aortic allografts and induces early latency of viral infection.

Authors:  K B Lemström; J H Bruning; C A Bruggeman; I T Lautenschlager; P J Häyry
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

10.  Cytomegalovirus infection enhances smooth muscle cell proliferation and intimal thickening of rat aortic allografts.

Authors:  K B Lemström; J H Bruning; C A Bruggeman; I T Lautenschlager; P J Häyry
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.